Who
Frank Mottola
SVP, Chief Tech. Ops. Officer
Company insider
Files Form 4 as: SVP, Chief Tech. Ops. Officer, Supernus Pharmaceuticals.
In numbers
- Trades disclosed
- 121
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $2.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 21 Feb 2020
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —1,650 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $37K797 at $46.57 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,650 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,650 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —1,650 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $37K797 at $46.57 | filing |
| 29 Jul 2026filed 31 Jul 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,650 at $0.00 | filing |
| 29 Jul 2026filed 31 Jul 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,650 at $0.00 | filing |
| 9 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $87K1,623 at $53.65 | filing |
| 9 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $87K1,623 at $53.65 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $98K1,793 at $54.73 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $98K1,793 at $54.73 | filing |
| 28 Feb 2026filed 3 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 28 Feb 2026filed 3 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,875 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $50K977 at $50.69 | filing |
News
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026SUPN · manilatimes.net · 19 Oct 2026Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveySUPN · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Frank Mottola; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.